Claims for Patent: 6,033,665

Summary for Patent: 6,033,665

Title:	Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
Abstract:	The invention is directed to compositions and methods for modulating the adhesion of leukocytes to brain endothelial cells. More specifically, the present invention relates to the use of reagents to inhibit the binding of VLA-4 leukocyte cell surface receptors to brain endothelial adhesion molecules. Also provided are compositions and methods for treating brain inflammation. A method of inducing brain inflammation as well as an assay for testing anti-inflammatory agents is also provided.
Inventor(s):	Yednock; Theodore A. (Fairfax, CA)
Assignee:	Elan Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:	08/457,847
Patent Claims:	1. A method for inhibiting or ameliorating brain inflammation comprising administering a reagent capable of inhibiting binding of leukocyte cell surface receptor VLA-4 to brain endothelial cell adhesion molecule VCAM-1. 2. In a method for treating chronic inflammatory brain disease, the improvement comprising administering a therapeutically effective dosage of a reagent that inhibits leukocyte cell surface receptor VLA-4 from binding to a brain endothelial adhesion molecule VCAM-1. 3. The method of claim 1 or 2, wherein the brain inflammation is associated with multiple sclerosis, experimental autoimmune encephalomyelitis or meningitis. 4. The method of claim 3, wherein the reagent is selected from the group consisting of an antibody, an antibody fragment thereof and a peptide. 5. The composition of claim 3, wherein the reagent is directed against leukocyte cell surface receptor VLA-4. 6. The method of claim 5, wherein the reagent is directed against the .alpha.4 subunit of leukocyte cell surface receptor VLA-4. 7. The method of claim 5, wherein the reagent binds to the .alpha.4 subunit of VLA-4 only in association with the .beta.1 subunit. 8. The method of claim 4, wherein the reagent is a monoclonal antibody. 9. A method of treating a pathology associated with an accumulation of leukocytes in the central nervous system of a subject comprising administering to the subject an effective amount of the pharmaceutical composition comprising a reagent chosen from the group consisting of an antibody, an antibody fragment thereof and a peptide, which reagent is capable of inhibiting binding of leukocyte cell surface receptor VLA-4 to brain endothelial cell adhesion molecule VCAM-1, and a pharmaceutically-acceptable carrier, thereby alleviating the pathology associated with an accumulation of leukocytes in the central nervous system of the subject. 10. A method of treating a pathology associated with an accumulation of leukocytes in the central nervous system of a subject comprising administering to the subject an effective amount of the pharmaceutical composition for inhibiting or ameliorating multiple sclerosis, experimental autoimmune encephalomyelitis or meningitis, comprised of at least one reagent that is an antibody, a fragment thereof, or a peptide, which reagent inhibits binding of leukocyte cell surface receptor VLA-4 to brain endothelial adhesion molecule VCAM-1, and a pharmaceutically-acceptable carrier, thereby treating the pathology associated with an accumulation of leukocytes in the central nervous system of the subject. 11. A method for treating multiple sclerosis, comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising a reagent chosen from the group consisting of comprising an antibody, an antibody fragment thereof and a peptide, which reagent is capable of inhibiting binding of leukocyte cell surface receptor VLA-4 to brain endothelial cell adhesion molecule VCAM-1, and a pharmaceutically-acceptable carrier, thereby alleviating the pathological condition associated with multiple sclerosis. 12. The method of claim 11, wherein the pathological condition is impaired nerve condition. 13. The method of claim 11, wherein the pathological condition is paralysis .

Details for Patent 6,033,665

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	11/23/2004		2017-03-07

International Patent Family for US Patent 6,033,665

Country	Patent Number	Estimated Expiration
Canada	2066738
European Patent Office	0493444
Japan	2002284700
Japan	3308526
Japan	H05503920